Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24414067 | 0.92 | BACE1 (0.46) | BACE1MDM4TP53MDM2CASP3 | |
| SCHEMBL29540058 | 0.91 | BACE1 (0.45) | BACE1MDM4TP53MDM2CASP3 | |
| SCHEMBL15083093 | 0.91 | BACE1 (0.45) | BACE1MDM4TP53MDM2CASP3 | |
| SCHEMBL25657642 | 0.89 | BACE1 (0.44) | BACE1MDM4TP53MDM2CASP3 | |
| SCHEMBL6163763 | 0.89 | BACE1 (0.44) | BACE1MDM4TP53MDM2CASP3 | |
| SCHEMBL6163754 | 0.89 | BACE1 (0.44) | BACE1MDM4TP53MDM2CASP3 | |
| SCHEMBL21838234 | 0.88 | BACE1 (0.44) | BACE1MDM4TP53MDM2CASP3 | |
| SCHEMBL21838232 | 0.88 | BACE1 (0.44) | BACE1MDM4TP53MDM2CASP3 | |
| SCHEMBL25657640 | 0.88 | BACE1 (0.44) | BACE1MDM4TP53MDM2CASP3 | |
| SCHEMBL2853531 | 0.87 | MDM2 (0.45) | BACE1MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | BACE1 1136/4885MDM4 441/4885TP53 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.